Thromboelastography measurements of whole blood from factor VIII-deficient mice supplemented with rFVIII.
The rotational thromboelastography (ROTEG) assay system allows the real-time analysis of clot formation (fibrin formation) in a whole-blood assay format. The ROTEG system provides significant advantages over the current plasma-based assay systems as it includes the important interactions between cellular and plasmatic coagulation factors. We have employed the ROTEG system to characterize clot formation dynamics in factor VIII- deficient mouse whole blood and examined the ability of recombinant FVIII (rFVIII) supplementation to restore the normal phenotype. The ability to generate a clear dose-response relationship by adding rFVIII to FVIII-deficient murine whole blood (FVIII-/-) demonstrates the feasibility of this approach. A dose-response from 1 U to 0.00001 U mL(-1) demonstrates the enhanced sensitivity of the ROTEG system. Further characterization of this experimental approach may provide a potential tool for comparing the activity of FVIII concentrates and/or evaluating FVIII mutants.
Landskroner
K A
KA
Bayer Healthcare, Biological Products Division, Research Triangle Park, NC 27709, USA. kyle.landskroner.b@bayer.com
Olson
N C
NC
Jesmok
G J
GJ
D000818:Animals; D001792:Blood Platelets / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005169:Factor VIII / Q000008:administration & dosage; D006467:Hemophilia A / Q000503:physiopathology*; D051379:Mice; D018345:Mice, Knockout; D013916:Thrombelastography / Q000379:methods*; D013917:Thrombin / Q000502:physiology*; D013997:Time Factors
C078147:F8 protein, human; D005169:Factor VIII; D013917:Thrombin